IBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD HorizonIBD Horizon
HIBD Horizon

Part 4 · The future · 17/22

The treatments on the way

Crohn's disease and ulcerative colitis: every molecule in Phase 3 or under review for authorisation.

How a medicine reaches us
Phase 1Is it safe? A few dozen people.
Phase 2Does it work? A few hundred.
Phase 3Confirming it on a large scale. Hundreds to thousands.
AuthorisedYour doctor can prescribe it.
Reading the bar:blue = stage passed, yellow = stage under way.
Already arrived in Europe in recent yearsVelsipity (UC, 2024), Skyrizi (UC, 2024), Omvoh (UC 2023, Crohn's 2025), Tremfya (Crohn's and UC, 2025). Stelara biosimilars are bringing prices down, and a first Entyvio biosimilar is under review in Europe. Ask your gastro which of these may concern you.

Anti-TL1A drugs: a brand-new family

They block TL1A, a signal that keeps inflammation going and encourages scarring in the gut.

Tulisokibart

MSD · Infusion then injection

Pathway: TL1A
UCPhase 3: goal met (June 2026), figures not yet released
Crohn'sPhase 3 under way
Possible arrival: around 2028

Duvakitug

Sanofi and Teva · Infusion then injection

Pathway: TL1A

Phase 2b: 58% remission in UC at 44 weeks, among the 130 patients who had responded at the start of treatment (no placebo).

UCPhase 3 under way
Crohn'sPhase 3 under way
Possible arrival: 2028-2029

Afimkibart

Roche · Infusion then injection

Pathway: TL1A

Also being tested in children.

UCPhase 3, results expected in 2027
Crohn'sPhase 3 under way
Possible arrival: 2028-2029

The anti-IL-23 family (Skyrizi, Omvoh, Tremfya)

They cut off IL-23, a messenger that gives the order to inflame the gut.

Icotrokinra

Johnson & Johnson · Tablet

Pathway: IL-23 receptor

The first tablet that blocks the IL-23 receptor. Already approved in the US for psoriasis (March 2026).

UCPhase 3 under way
Crohn'sPhase 2b/3 under way
Possible arrival: after 2028

Skyrizi: subcutaneous induction

risankizumab, AbbVie · Injection

Pathway: IL-23

Maintenance is already given as an injection at home. New: the start of treatment too, with 4 injections at home (an injector stuck on the skin) instead of 3 infusions in hospital.

Crohn'sApproved in the US on 23 October 2026, Europe still to come
Possible arrival: soon in Europe

Two drugs in one

Two known brakes on inflammation are combined to go further than one alone.

JNJ-4804

Tremfya + Simponi, Johnson & Johnson · Injection

Pathway: IL-23 + TNF

DUET programme: Phase 2b met its goals in more than 1,000 patients (May 2026).

UCPhase 2b met its goals, Phase 3 announced
Crohn'sPhase 2b met its goals, Phase 3 announced
Possible arrival: 2029 or later

New tablets

Two new ways to calm the gut, with no injection.

Obefazimod

Abivax, a French company · Tablet

Pathway: miR-124

Boosts a natural brake on inflammation. Among those who had responded in the first 8 weeks: 51% remission at 44 weeks versus 10% on placebo.

UCPhase 3 met its endpoints, US filing planned for late 2026
Crohn'sPhase 2b, results mid-2027
Possible arrival: UC 2027-2028

Omilancor

NImmune · Tablet

Pathway: LANCL2

Rebalances the defences in the gut wall.

UCPhase 3 announced by the company, results not yet published
Crohn'sPhase 2
Possible arrival: uncertain